<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780754</url>
  </required_header>
  <id_info>
    <org_study_id>BE-2-27</org_study_id>
    <nct_id>NCT00780754</nct_id>
  </id_info>
  <brief_title>Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia</brief_title>
  <official_title>Effect of 5Î± Reductase Inhibitor Dutasteride on the Prevention of the Prostate Cancer in Men With High Grade Intraepithelial Neoplasia of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaunas University of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaunas University of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with diagnosis of HPIN were enrolled. Patients were randomized into two groups:
      dutasteride treatment group and watchful waiting strategy group. According to the study
      protocol the subjects would undergo 10 core biopsies after 6, 12, 24, and 36 months after
      randomization.

      There are assessed the rate of prostate cancer at repeated transrectal ultrasound guided
      biopsies and the effect of 5 alfa reductase inhibitor (dutasteride) on prevention of prostate
      cancer development for patients with high grade intraepithelial neoplasia (HPIN).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of prostate cancer at repeated transrectal ultrasound guided biopsies in case of HPIN</measure>
    <time_frame>6, 12, 24, and 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect of 5 alfa reductase inhibitor (dutasteride) on prevention of prostate cancer development for patients with high grade intraepithelial neoplasia (HPIN).</measure>
    <time_frame>6, 12, 24, and 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>dutasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>watchful waiting strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dutasteride</intervention_name>
    <description>0.5mg</description>
    <arm_group_label>dutasteride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>prostate biopsy</intervention_name>
    <description>prostate biopsy</description>
    <arm_group_label>dutasteride</arm_group_label>
    <arm_group_label>watchful waiting strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age - 40-80 years

          2. HPIN on prostate biopsy specimens

          3. PSA below 20ng/ml

          4. No hormone therapy or radiation in pelvic region

          5. No previous treatment with 5alfa reductase inhibitors

          6. Signed Subject Information and Informed Subject Consent Form.

        Exclusion Criteria:

        1. Not compensate cardiovascular, pulmonary, hepatic or renal functions, neurological,
        psychiatric disease, sepsis, etc.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daimantas Milonas, assist professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaunas Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology dep. of Kaunas University of Medicine</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2008</study_first_submitted>
  <study_first_submitted_qc>October 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lithuanian University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Stasys Auskalnis</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>chemoprevention</keyword>
  <keyword>dutasteride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

